MSF Donation for Prostate Cancer UK
smaller text tool iconmedium text tool iconlarger text tool icon

MSFHeader

Prostate Cancer UK has announced that a new study has found that the presence of a specific protein can distinguish between prostate cancers that are aggressive and need further treatment from those that may never seriously harm the patient.

The Masonic Samaritan Fund (MSF) donated £34,625 towards the study earlier this year at the University of Cambridge. Dr Hayley Whitaker, Research Developer and Lead Researcher for Prostate Cancer UK accepted the donation from the MSF CEO Richard Douglas. The Masonic Samaritan Fund is delighted to have made a donation which will have a real impact on advanced medical diagnostics.


Richard Douglas, MSF CEO with Dr Hayley Whitaker at the University of Cambridge

 

Dr Whitaker explained that the presence of these specific proteins now called NAALADL2, can be measured with a blood test, saving many men undergoing invasive tests and unnecessary worry, whilst allowing faster, targeted treatment for men with aggressive prostate cancers. The hope is that this test will be available on the NHS in the next five to ten years.

Richard Douglas said: "Accurate diagnosis of prostate cancer is the starting point to help men survive and have a better quality of life post treatment. With over 10,000 men dying annually from this disease, that is one per hour, we're delighted to have made a significant contribution towards the funding Dr Whitaker needed to identify prostate cancers through a low cost blood test."

 

 

United Grand Lodge of England